clinical trial · NCT07813572
ZG005 Plus Bevacizumab vs Sintilimab Plus Bevacizumab as First-Line Therapy for Advanced Hepatocellular
Suzhou Zelgen Biopharmaceuticals Co.,Ltd·phase3·not yet recruiting·n = 600
Hepatocellular CarcinomaZG005 for InjectionBevacizumab ( Avastin)SintilimabBevacizumab
brief summary
The purpose of the study is to evaluate the efficacy of ZG005 combined with bevacizumab compared with sintilimab combined with bevacizumab in the first-line treatment of participants with advanced HCC
started
Sep 1, 2026
primary completion
Sep 1, 2031
completion
Sep 1, 2032
last updated
Sep 10, 2026
official title
A Phase 3, Randomized, Open-Label, Active-Controlled, Multicenter Study of ZG005 in Combination With Bevacizumab Versus Sintilimab in Combination With Bevacizumab in the First-Line Treatment of Advanced Hepatocellular Carcinoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol